The Association of Primary Biliary Cirrhosis and Systemic Sclerosis is not Accounted for by Cross Reactivity Between Mitochondrial and Centromere Antigens

Whyte, Jean; Hough, David M.; Maddison, Peter J.; McHugh, Neil

doi:10.1006/jaut.1994.1030

Cited by 20 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMAs, normally regarded as a specific marker for primary biliary cirrhosis (PBC), occur in around 8% of SSc patients [101,102] and CENP autoantibodies have been reported in 9-29% of patients with PBC, lending support to the observation that there is an overlap between these two diseases [103][104][105]. Rigamonti et al [106 ] reviewed 43 patients with SSc and PBC among 580 PBC patients.…”

Section: Mitochondriamentioning

confidence: 93%

Update on autoantibodies in systemic sclerosis

Walker

Fritzler

2007

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Mitochondriamentioning

confidence: 93%

Update on autoantibodies in systemic sclerosis

Walker

Fritzler

2007

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…Tojo et al [43] described a subgroup of PBC patients who had associated CREST symptoms and a better prognosis than patients with PBC alone [43]. These patients develop AMA and ACA, with no crossreactivity between the two autoantibodies [44]. Conversely, 7.6% to 25% of patients with scleroderma have AMA, which target the 70-kd autoantigen of PBC [42].…”

Section: Antimitochondrial Antibodiesmentioning

confidence: 96%

Antibodies in scleroderma: Direct pathogenicity and phenotypic associations

Chung

Utz²

2004

Curr Rheumatol Rep

View full text Add to dashboard Cite

Scleroderma is an autoimmune disease involving endothelial cell damage and fibroblast overproduction of extracellular matrix. Several autoantibodies present in the sera of patients with scleroderma, including anti-endothelial cell, antifibroblast, anti-matrix metalloproteinase, and antifibrillin-1 antibodies, may directly contribute to disease pathogenesis. Scleroderma also is characterized by the presence of antinuclear and antinucleolar antibodies, which correlate with particular phenotypes. These include antitopoisomerase-I, anticentromere, antihistone, anti-polymyositis/scleroderma, anti-Th/To, anti-U3-small nucleolar ribonucleoprotein particle, anti-U1-small nuclear ribonucleoprotein particle, anti-RNA polymerase, and anti-B23 antibodies. Other antibodies classically associated with other autoimmune diseases, such as antiphospholipid, antineutrophil cytoplasmic, and antimitochondrial antibodies, also have been described in patients with scleroderma. This review will summarize the various autoantibodies associated with scleroderma, their putative pathogenic roles, and their phenotypic correlations.

show abstract

“…More recently, 70% of PBC/SSc overlap patients were shown to be ACA positive, compared to 0% of patients with PBC alone [2]. ACA is consistently found at higher frequencies within the PBC/SSc overlap population [98,99] and, importantly, this cannot be accounted for by cross-reactivity between anti-centromere and anti-mitochondrial antigens [160]. A recent study that included 817 patients with SSc reported 16 patients with concomitant presence of PBC.…”

Section: Clinical Significance Of Anti-centromere Antibodies In Pbc Pmentioning

confidence: 96%